(-0.03%) 5 186.31 points
(0.18%) 38 955 points
(-0.14%) 16 309 points
(0.32%) $78.63
(0.27%) $2.21
(-0.03%) $2 323.40
(0.40%) $27.66
(-0.43%) $984.15
(0.11%) $0.931
(0.08%) $10.91
(0.15%) $0.801
(0.60%) $91.99
Live Chart Being Loaded With Signals
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...
Stats | |
---|---|
本日の出来高 | 61 456.00 |
平均出来高 | 22 310.00 |
時価総額 | 132.86B |
EPS | INR0 ( 2024-02-08 ) |
次の収益日 | ( INR0 ) 2024-05-28 |
Last Dividend | INR16.00 ( 2023-07-14 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 95.68 |
ATR14 | INR4.75 (0.09%) |
ボリューム 相関
AstraZeneca Pharma India 相関
10 最も正の相関 | |
---|---|
SEYAIND.NS | 0.834 |
10 最も負の相関 | |
---|---|
CONTROLPR.NS | -0.807 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
AstraZeneca Pharma India 相関 - 通貨/商品
AstraZeneca Pharma India 財務諸表
Annual | 2022 |
収益: | INR10.03B |
総利益: | INR5.45B (54.37 %) |
EPS: | INR39.72 |
FY | 2022 |
収益: | INR10.03B |
総利益: | INR5.45B (54.37 %) |
EPS: | INR39.72 |
FY | 2022 |
収益: | INR8.06B |
総利益: | INR4.48B (55.63 %) |
EPS: | INR24.60 |
FY | 2021 |
収益: | INR8.09B |
総利益: | INR4.78B (59.12 %) |
EPS: | INR37.30 |
Financial Reports:
No articles found.
AstraZeneca Pharma India Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR8.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR16.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR3.70 | 2003-04-17 |
Last Dividend | INR16.00 | 2023-07-14 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR184.10 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 1.47 | -- |
Div. Sustainability Score | 4.66 | |
Div.Growth Potential Score | 2.21 | |
Div. Directional Score | 3.44 | -- |
Year | Amount | Yield |
---|---|---|
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0 | 0.00% |
2019 | INR1.000 | 0.07% |
2020 | INR2.00 | 0.08% |
2021 | INR2.00 | 0.04% |
2022 | INR8.00 | 0.26% |
2023 | INR16.00 | 0.48% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SMSPHARMA.NS | Ex Dividend Junior | 2023-09-22 | Annually | 18 | 0.12% | |
MINDTECK.NS | Dividend Junior | 2023-08-04 | Sporadic | 8 | 0.28% | |
HBSL.NS | Dividend Junior | 2023-08-11 | Sporadic | 12 | 0.78% | |
BEPL.NS | Dividend King | 2023-07-25 | Semi-Annually | 20 | 4.91% | |
RADICO.NS | Dividend Junior | 2023-09-14 | Annually | 22 | 0.24% | |
KHAICHEM.NS | No Dividend Player | 2023-07-21 | Annually | 5 | 0.32% | |
EMAMIPAP.NS | Dividend Junior | 2023-09-05 | Annually | 3 | 0.56% | |
AJANTPHARM.NS | Dividend Knight | 2023-08-04 | Annually | 23 | 0.57% | |
SUNTV.NS | Dividend Knight | 2023-08-22 | Quarterly | 19 | 1.94% | |
NAVNETEDUL.NS | Dividend Junior | 2023-08-07 | Annually | 22 | 1.10% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.116 | 1.500 | 7.67 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.62 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 128.03 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 9.89 | 2.00 | 6.70 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 9.89 | 2.00 | 5.06 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.518 | 1.000 | 4.71 | 4.71 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.145 | 1.000 | 9.10 | 9.10 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 4.66 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 92.61 | 1.000 | 0.747 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.11 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 9.89 | 2.00 | 6.70 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.310 | 1.500 | 2.25 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 9.89 | 2.00 | 6.70 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -2.73 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0207 | 1.000 | -1.984 | 0 | [0.1 - 0.5] |
Total Score | 2.21 |
AstraZeneca Pharma India
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。